The resistance to radiotherapy in lung cancer can be attributed to vasculogenic mimicry (VM) to some extent. Celecoxib (CXB). a selective inhibitor of cyclooxygenase-2 (COX-2). is reported as a radiosensitizer in non-small cell lung cancer (NSCLC). https://www.itsmajorlook.com/